AIMS To evaluate the clinical significance of coatomer protein complex subunit beta 2 (COPB2) in patients with glioma using a bioinformatics analysis. METHODS Oncomine, GEO, and The Cancer Genome Atlas databases were used to examine the COPB2 transcript levels in glioma tissues. Gene expression profiles with clinical information from low-grade glioma and glioblastoma (GBM) projects were analyzed for associations between COPB2 expression and clinicopathologic characteristics. Kaplan-Meier survival and Cox regression analyses were used for survival analysis. Gene set enrichment analysis (GSEA) was conducted to screen the pathways involved in COPB2 expression. Gene set variation analysis (GSVA) and correlograms were performed to verify the correlations between COPB2 and inflammatory responses. Canonical correlation analyses examined whether COPB2-high patients have more infiltrating inflammatory and immune cells. RESULTS COPB2 was highly expressed in gliomas and high COPB2 expression correlated with shorter overall survival time and several poor clinical prognostic variables. GSEA indicated that some immune-related pathways and other signaling pathways in cancer were associated with the COPB2-high phenotype. The GSVA and canonical correlation analysis demonstrated that COPB2 expression was closely linked to inflammatory and immune responses, and higher immune cell infiltration. CONCLUSIONS COPB2 may be a potential prognostic biomarker and an immunotherapeutic target for glioma.

中文翻译：

---

COPB2的高表达预示不良结果：胶质瘤的潜在治疗靶点。

目的通过生物信息学分析评估脑胶质瘤患者涂层蛋白复合物亚基β2（COPB2）的临床意义。方法使用Oncomine，GEO和Cancer Genome Atlas数据库检查神经胶质瘤组织中的COPB2转录水平。分析了来自低级神经胶质瘤和胶质母细胞瘤（GBM）项目的临床信息的基因表达谱，分析了COPB2表达与临床病理特征之间的关联。Kaplan-Meier生存和Cox回归分析用于生存分析。进行基因集富集分析（GSEA）以筛选参与COPB2表达的途径。进行基因组变异分析（GSVA）和相关图以验证COPB2与炎症反应之间的相关性。典型的相关分析检查了高COPB2的患者是否具有更多的浸润性炎症和免疫细胞。结果COPB2在脑胶质瘤中高表达，而COPB2高表达与较短的总生存时间和一些不良的临床预后相关。GSEA指出，癌症中的某些免疫相关途径和其他信号传导途径与COPB2高表型有关。GSVA和典范的相关性分析表明，COPB2表达与炎症和免疫反应以及更高的免疫细胞浸润密切相关。结论COPB2可能是神经胶质瘤的潜在预后生物标志物和免疫治疗靶标。结果COPB2在脑胶质瘤中高表达，而COPB2高表达则与较短的总生存时间和一些不良的临床预后相关。GSEA指出，癌症中的某些免疫相关途径和其他信号传导途径与COPB2高表型有关。GSVA和典范的相关性分析表明，COPB2表达与炎症和免疫反应以及更高的免疫细胞浸润密切相关。结论COPB2可能是神经胶质瘤的潜在预后生物标志物和免疫治疗靶标。结果COPB2在脑胶质瘤中高表达，而COPB2高表达与较短的总生存时间和一些不良的临床预后相关。GSEA指出，癌症中的某些免疫相关途径和其他信号传导途径与COPB2高表型有关。GSVA和典范的相关性分析表明，COPB2表达与炎症和免疫反应以及更高的免疫细胞浸润密切相关。结论COPB2可能是神经胶质瘤的潜在预后生物标志物和免疫治疗靶标。GSVA和典范的相关性分析表明，COPB2表达与炎症和免疫反应以及更高的免疫细胞浸润密切相关。结论COPB2可能是神经胶质瘤的潜在预后生物标志物和免疫治疗靶标。GSVA和典范的相关性分析表明，COPB2表达与炎症和免疫反应以及更高的免疫细胞浸润密切相关。结论COPB2可能是神经胶质瘤的潜在预后生物标志物和免疫治疗靶标。